NovaGo Therapeutics AG

NovaGo Therapeutics is a Swiss biotech startup company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in brain and retina. NovaGo Therapeutics is pursuing the development of its lead molecule, NG004, in two indications, regenerative therapy for ischemic stroke and novel therapy for diabetic retinopathy.
NovaGo is currently financed through Series A investment round of 10 million Swiss Francs and is launching its Series B financing round of CHF 46 million. The proceeds will cover clinical development activities up to Phase II Proof-of-Concept Clinical trials and general corporate.  Clinical studies are planned to start in Q2 2021.